Aircraft Medical Limited (Aircraft Medical), the UK-based medical devices company, has added 25 new staff to its R&D, business development and sales teams since January 2009. The appointment of key staff is in line with the company’s commitment to expanding the company’s Anaesthesia & Critical Care offering and increasing its focus on business development and R&D activities.
Aircraft has also enhanced R&D capabilities in order to develop a broader range of Anaesthesia & Critical Care devices for its customers. It has recruited a number of new executives with experience of working with leading companies including Sony, Nokia and Philips.
Similarly, the company has expanded its electronics team. These personnel have developed technology for clients such as IBM, Intel and Nokia, and a range of other technology companies. Aircraft also welcome to the company an in-house Tooling Designer who has led the design of medical device production tooling for clients such as Smiths, GlaxoSmithKline and GE. Aircraft now has a full cycle development capability, from clinical research and ideas creation, to product development and production.
Aircraft’s Sales & Marketing infrastructure has been expanded to develop and grow the business with both existing and new distributors in new markets. The enlarged team benefits from new personnel with both direct sales and distributor support experience gained at large companies such as Datex-Ohmeda (now-GE), Cardinal Health and Hudson, as well as smaller medical technology companies.
Matt McGrath, chief executive officer of Aircraft Medical, said: “Over the last several months, Aircraft has been able to attract a number of very high calibre individuals, with proven track records at a variety of leading technology, pharmaceutical and life science companies. These appointments substantially improve our capabilities and represent a key milestone as the company’s transforms into a global medical technology business.”
Aircraft expects to continue to recruit over the rest of 2009 and in 2010 to match the company’s strong growth prospects.